U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.

Pfizer: I'm Still Expecting A Massive Rebound

09:00am, Wednesday, 18'th Mar 2026
Pfizer Inc.'s non-COVID operational revenue grew 9% in Q4, successfully offsetting the ongoing decline in pandemic-related sales and signaling a structural shift toward long-term growth. The Seagen in
Pfizer and Novo Nordisk look cheap in more ways than one. Pipeline progress could help improve their financial results.
After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing.
Captrust Financial Advisors lowered its holdings in shares of Pfizer Inc. (NYSE: PFE) by 0.9% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund ow
The first severe case of the virus has been detected in New York.
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% ​in patients with breast cancer.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versu
The university spinout investor posted a 13% increase in net asset value per share after Pfizer's acquisition of obesity drug developer Metsera IP Group PLC (LSE:IPO), the London-listed investor in un
Pfizer's revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it's faced a drop in that demand and losses of exclusivity con
Pfizer and Bristol Myers are racing to strengthen oncology portfolios through deals, new drugs and pipelines ??? investors are weighing which stock stands out.
Enterprise Products Partners is poised to benefit from increased demand for natural gas and natural gas liquids. Pfizer should be able to successfully navigate its looming patent cliff.
Ameriprise Financial Inc. grew its stake in Pfizer Inc. (NYSE: PFE) by 48.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The inst
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE